User login
Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.
Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.
Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.
Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.
Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.
Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.
Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.
Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.
Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.
Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.
Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.
Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.
Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.
Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.
Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.